2Alberti KG,Zimmet PZ,Shaw JE.The metabolic syndrome a new world-wide definition from the International Diabetes Federation consensus[J].Lancet,2005,183(4):175.
3Chapman MJ.Metabolic syndrome and type 2 diabetes:lipidand physiological consequences[J].Diab Vasc Dis Res,2007,4:S5.
4Kopelman P.Health risks associated with overweight and obesity[J].Obes Rev,2007,8(Suppl 1):13.
5Baigent C,Keech A,Kearney PM,et al.Cholesterol Treatment Trialists′ (CTT) Collaborators.Efficacy and safety of cholesterollowering treatment:prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins[J].Lancet,2005,366:1267.
6Topol EJ.Intensive statin therapy a sea change in cardiovascular prevention[J].N Engl J Med,2004,350:1562.
7Ginsberg HN.REVIEW:Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia[J].J Clin Endocrinol Metab,2006,91:383.
8Singh V,Deedwania P.Reducing morbidity and mortality in high risk patients with statins[J].Vasc Health Risk Manag,2009,5:495.
9Kinlay S.Low-density lipoprotein-dependent and –independent effects of cholesterol-lowering therapies on C-reactive protein:a meta-analysis[J].J Am Coll Cardiol,2007,49:2003.
10Kinlay S,Schwartz GG,Olsson AG,et al.Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study[J].Circulation,2003,108:1560.
